P53immunostained cell nuclei segmentation in tissue images of oral squamous cell carcinoma

K. A. Hameed,A. Banumathi,U. Gurunathan

DOI: https://doi.org/10.1007/s11760-016-0953-y

2017-02-01

Abstract:

What problem does this paper attempt to address?

Effect of Ixekizumab on Enthesitis-related arthritis non-responsive to anti-TNF treatment, a case report

Qi Zheng,Xiaohui Ma,Mengmeng Zhong,Yan Zhang,Meiping Lu

DOI: https://doi.org/10.21203/rs.3.rs-2725312/v1

2023-01-01

Abstract:Abstract Background: To describe the effectiveness of Ixekizumab on a patient with ERA who was refractory to conventional treatment and TNF inhibitors. Case presentation: A 15-year-old boy who manifested as swollen knees, bilateral ankle arthritis, sausage toes and low-grade fever was diagnosed as Enthesitis related arthritis. There was one episode of uveitis three years before the onset of joint symptoms. The patient had a high level of inflammation (ESR to 107 mm/hour, CRP to 248.77 mg/L) with increased level of serum IL-6 and VEGF. Combination therapy of NSAIDs with sulfasalazine, Adalimumab, Infliximab, low dose steroid, Golimumab and Tofacitinib were applied correspondingly. The systemic inflammation of this patient (not including swollen toes and enthesitis) got a little better with oral steroids, but intensified again when steroid was weaned. Ixekizumab (80mg, Q2W twice, then 80mg Q4W) combined with oral methotrexate were then applied for this patient. ESR and CRP decreased into normal level with quick alleviation of arthritis within the first month of treatment. A persistent clinical remission was achieved by using Ixekizumab in the following two years of therapy. Apart from slight redness and swelling at the injection site, no significant side effects were observed during follow up. Conclusion: Ixekizumab can be a substitutive therapy for ERA patients who were unresponsive to traditional therapy or anti-TNF treatment.
Efficacy of Paravertebral Injection of Interferon-α2b combined with High-Voltage Long-Term Pulsed Radiofrequency in DRG in mitigation of Postherpetic Neuralgia: A Retrospective Study

Jie Pan,Yong Fei,Ming Yao,Bing Huang,Longsheng Xu,Beibei Liu

DOI: https://doi.org/10.1016/j.wneu.2024.01.008

IF: 2.21

2024-01-10

World Neurosurgery

Abstract:Objective This investigation aims to evaluate the effectiveness of the paravertebral injection of recombinant human interferon-α2b in conjunction with high-voltage, long-term pulsed radiofrequency (PRF) in DRG in the mitigation of postherpetic neuralgia (PHN). Methods This retrospective study was performed on 84 individuals suffering from acute PHN. The participants were divided into three groups. Group H: Treat with interferon-α2b combined with high-voltage long-term PRF; Group C: Treat with high-voltage long-term PRF; Group I: Treat with the interferon-α2b. All patients in the three groups were orally administered 5 mg of morphine hydrochloride quick-release tablets when there was a burst of pain during the treatment. The pain numerical rating score (NRS), IL-6, Gal-3, and the incidence of PHN were documented prior to and following therapy. Results The pain intensity of all individuals decreased following therapy. In comparison with group C, the group H NRS scores significantly reduced at 4, 8, and 12 weeks following therapy, and the PHN incidence was significantly lesser. In comparison with that prior treatment, the recommended dosage of gabapentin capsules and morphine hydrochloride tablets with an immediate release was reduced in group H. In comparison with group C, the gabapentin orally administrated capsule and morphine hydrochloride in group H reduced significantly after treatment. There were no serious adverse reactions in the three groups. Conclusion Within the context of treatment of acute PHN, the injection of interferon-α2b in conjunction with high-voltage, long-term application of PRF is more effective than the PRF or injection of interferon-α2b alone.

surgery,clinical neurology
Electroacupuncture on Hemifacial Spasm and Temporomandibular Joint Pain Co-Morbidity: A Case Report

Jian-peng Huang,Zhan-mou Liang,Qi-wen Zou,Jie Zhan,Wen-ting Li,Sheng Li,Kai Li,Wen-bin Fu,Jian-hua Liu

DOI: https://doi.org/10.3389/fneur.2022.931412

IF: 3.4

2022-06-28

Frontiers in Neurology

Abstract:Hemifacial spasm (HFS) and temporomandibular joint (TMJ) pain are common facial diseases which cause depression, anxiety, insomnia, and poor quality of life. However, currently there are still no effective therapies to treat HFS and TMJ. Electroacupuncture (EA) has advantages of safety, rapid work, easy operation and convenience. Here, we reported a case of a 50-year-old woman who presented with irregular spasm of eyelids and facial muscles on the left side, and TMJ pain on the right side. The patient had been treated with carbamazepine (20mg per day) and alternative therapies for a year, but still not much improvement in the symptoms. The scores of the Jankovic Rating Scale (JRS), global rating scale (GRS), and visual analog scale (VAS) were 7, 60, and 7 points, respectively. The EMG test showed that the spastic side had higher R1 amplitude, longer R2 duration, and larger R2 area than the non-spasmodic side, and the occurrence rate of the lateral spread responses (LSR) in the Orbicularis oris and the Orbicularis oculi muscle was 60% and 40%, respectively. We considered this patient had left HFS and right TMJ pain. EA was successfully undertaken for two periods over 30 weeks. After EA, JRS and VAS were reduced sharply, and the symptoms of HFS were stable without recurrence. However, the frequency of the lower eyelid increased gradually during the 6-month follow-up. These findings reveal that EA with the frequency of 2 Hz and intensity of ~ 1–2 mA may be a benefit for alleviating symptoms of HFS and TMJ pain without adverse reaction. The potential mechanisms of EA in HFS and TMJ pain co-morbidity involve brain stem mechanism and DNIC mechanism for distal acupuncture and segmental mechanism for local acupuncture analgesia.

neurosciences,clinical neurology
Primary erythromelalgia mainly manifested by hypertensive crisis: A case report and literature review

Shuo Feng,Zhanwen He,Liping Que,Xiangyang Luo,Liyang Liang,Dongfang Li,Lijun Qin

DOI: https://doi.org/10.3389/fped.2022.796149

IF: 3.569

2022-08-17

Frontiers in Pediatrics

Abstract:Background: Primary erythrocytic (PEM) is a rare autosomal dominant single gene disease. Most of the changes of gene loci can be found by whole exon gene sequencing, and the clinical symptoms and patient survival can be improved by specific site-to-site drug treatment. The other manifestations of this patient population are not remarkable. After the application of common drugs, the toxicity and side effects can be limiting. In addition to other common clinical manifestations, we found that the only unique manifestation of this patient was hypertensive crisis. Following multidisciplinary diagnosis and treatment (MDT), we decided to first control hypertension to alleviate the acute and critical patients. However, after controlling the hypertensive crisis, we unexpectedly found that the clinical symptoms of the patients had been significantly improved. Therefore, we concluded that the use of antihypertensive drugs can treat erythematous limb pain with the clinical manifestation of hypertensive crisis. Here, we describe a typical PEM disease, primary clinical features, diagnosis and treatment. Methods: Medical records of an 8-year-old boy with PEM were analyzed retrospectively, which included clinical characteristics, follow-up information, and SCN9A (Sodium Voltage-Gated Channel Alpha Subunit 9) gene analysis. Results: The 8-year-old boy had complained of abnormal paresthesia in his feet and ankles with burning sensation and pain for 2 years. The skin of both lower legs was red and underwent ichthyosis and lichenification. Genetic analysis confirmed the existence of a SCN9A gene mutation. The symptoms were gradually improved by treating with intravenous drip and oral administration of nitroglycerin to slow his heart rhythm. Conclusion: Primary erythrocytic is characterized by skin ulceration, redness, elevated temperature, and severe burning pain primarily in both lower extremities. PEM can be diagnosed by genetic analysis. As this case demonstrates, treating with nitroglycerin as the drug of choice to control the hypertensive crisis significantly improved the symptoms of PEM and hypertension in this patient.

pediatrics
Procedural interventions for erythromelalgia: A narrative review

Jinnee UJ Lee,Janice E Ma,Julio C Sartori Valinotti,Thom W Rooke,Paola Sandroni,James C Watson,Mark DP Davis

DOI: https://doi.org/10.1177/1358863x241279427

2024-09-27

Vascular Medicine

Abstract:Vascular Medicine, Ahead of Print. Erythromelalgia is a rare disorder characterized by episodic burning pain with redness and warmth of the extremities. Topical and systemic medications are the mainstay of management. We reviewed the published evidence for using procedural interventions to manage erythromelalgia, including their proposed mechanism of action and possible adverse effects, and included information in this review on epidural infusion, sympathetic ganglion block, sympathectomy, pulsed radiofrequency, spinal cord stimulation, dorsal root ganglion stimulation, brain stimulation, transcranial magnetic stimulation, and botulinum toxin injections. Both successful and unsuccessful outcomes have been reported. Although these procedural interventions extend the therapeutic options for erythromelalgia, the evidence for their use is limited. Case reports and small case series comprise most of the evidence. Based on our review, a multidisciplinary approach to management may be needed for patients with erythromelalgia.

peripheral vascular disease
Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World

Yingxin Sun,Yifeng Cai,Jiannong Cen,Mingqing Zhu,Jinlan Pan,Qian Wang,Depei Wu,Suning Chen

DOI: https://doi.org/10.3389/fonc.2021.797825

IF: 4.7

2021-12-21

Frontiers in Oncology

Abstract:Several clinical trials have shown promising efficacy of pegylated interferon (Peg-IFN) in the first- and second-line polycythemia vera (PV) and essential thrombocythemia (ET). However, the efficacy and safety of Peg-IFN in the real world have rarely been reported. Hence, we conducted a prospective, single-center, single-arm, open exploratory study, which aimed to explore the hematologic response, molecular response, safety, and tolerability of patients with PV and ET treated with Peg-IFN in the real world. This study included newly diagnosed or previously treated patients with PV and ET, aged 18 years or older, admitted to the Department of Hematology of the First Affiliated Hospital of Soochow University from November 2017 to October 2019. The results revealed that complete hematological response (CHR) was achieved in 66.7% of patients with PV and 76.2% of patients with ET, and the molecular response was obtained in 38.5% of patients with PV and 50% of patients with ET after 48 weeks of Peg-IFN treatment. Peg-IFN is safe, effective and well tolerated in most patients. In the entire cohort, 4 patients (9.1%) discontinued treatment due to drug-related toxicity. In conclusion, Peg-IFN is a promising strategy in myeloproliferative neoplasms (MPNs), and Peg-IFN alone or in combination with other drugs should be further explored to reduce treatment-related toxicity and improve tolerability.

oncology
A New Dosing Regimen of Ropeginterferon Alfa-2B is Highly Effective and Tolerable: Findings from a Phase 2 Study in Chinese Patients with Polycythemia Vera

Jie Jin,Lei Zhang,Albert Qin,Daoxiang Wu,Zonghong Shao,Jie Bai,Suning Chen,Minghui Duan,Hu Zhou,Na Xu,Sujiang Zhang,Xuelan Zuo,Xin Du,Li Wang,Pei Li,Xuhan Zhang,Yaning Li,Jingjing Zhang,Wei Wang,Weihong Shen,Oleh Zagrijtschuk,Raymond Urbanski,Toshiaki Sato,Zhijian Xiao

DOI: https://doi.org/10.1186/s40164-023-00415-0

2023-01-01

Abstract:Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe with a starting dose of 100 µg (50 µg for patients receiving hydoxyurea) and intra-patient dose titrations up to 500 µg at 50 µg increments, which took approximately 20 or more weeks to reach a plateau dose level. This study aimed to assess ropeginterferon alfa-2b at an alternative dosing regimen with a higher starting dose and quicker intra-patient dose titrations, i.e., the 250–350–500 μg schema, in 49 Chinese patients with PV with resistance or intolerance to hydroxyurea. The primary endpoint of the complete hematologic response rate at treatment weak 24 was 61.2%, which was notably higher than 43.1% at 12 months with the approved dosing schema. The JAK2 V617F allele burden decreased from baseline to week 24 (17.8% ± 18.0%), with one patient achieving a complete molecular response. Ropeginterferon alfa-2b was well-tolerated and most adverse events (AEs) were mild or moderate. Common AEs included alanine aminotransferase and aspartate aminotransferase increases mostly at grade 1 or 2 levels. Patients did not present with jaundice or significant bilirubin level increase. No grade 4 or 5 AEs occurred. Seven patients (14.3%) experienced reversible, drug-related grade 3 AEs. No AEs led to treatment discontinuation. Ropeginterferon alfa-2b at the 250–350–500 μg regimen is highly effective and well-tolerated and can help patients achieve greater and rapid complete hematologic and molecular responses. Clinical Trial Registration: This trial is registered at ClinicalTrials.gov (Identifier: NCT05485948) and in China (China National Medical Products Administration Registration Number: CTR20211664).
Electroacupuncture Reduced Fibromyalgia-Pain-like Behavior through Inactivating Transient Receptor Potential V1 and Interleukin-17 in Intermittent Cold Stress Mice Model

Yu-An Yeh,Hsien-Yin Liao,I-Han Hsiao,Hsin-Cheng Hsu,Yi-Wen Lin

DOI: https://doi.org/10.3390/brainsci14090869

IF: 3.333

2024-08-30

Brain Sciences

Abstract:Fibromyalgia (FM) is a widespread musculoskeletal pain associated with psychological disturbances, the etiopathogenesis of which is still not clear. One hypothesis implicates inflammatory cytokines in increasing central and peripheral sensitization along with neuroinflammation, leading to an elevation in pro-inflammatory cytokines, e.g., interleukin-17A (IL-17A), enhanced in FM patients and animal models. The intermittent cold stress (ICS)-induced FM-like model in C57BL/6 mice has been developed since 2008 and proved to have features which mimic the clinical pattern in FM patients such as mechanical allodynia, hyperalgesia, and female predominance of pain. Electroacupuncture (EA) is an effective treatment for relieving pain in FM patients, but its mechanism is not totally clear. It was reported as attenuating pain-like behaviors in the ICS mice model through the transient receptor potential vanilloid 1 (TRPV1) pathway. Limited information indicates that TRPV1-positive neurons trigger IL-17A-mediated inflammation. Therefore, we hypothesized that the IL-17A would be inactivated by EA and TRPV1 deletion in the ICS-induced FM-like model in mice. We distributed mice into a control (CON) group, ICS-induced FM model (FM) group, FM model with EA treatment (EA) group, FM model with sham EA treatment (Sham) group, and TRPV1 gene deletion (Trpv1−/−) group. In the result, ICS-induced mechanical and thermal hyperalgesia increased pro-inflammatory cytokines including IL-6, IL-17, TNFα, and IFNγ in the plasma, as well as TRPV1, IL-17RA, pPI3K, pAkt, pERK, pp38, pJNK, and NF-κB in the somatosensory cortex (SSC) and cerebellum (CB) lobes V, VI, and VII. Moreover, EA and Trpv1−/− but not sham EA countered these effects significantly. The molecular mechanism may involve the pro-inflammatory cytokines, including IL-6, IL-17, TNFα, and IFNγ. IL-17A–IL-17RA play a crucial role in peripheral and central sensitization as well as neuroinflammation and cannot be activated without TRPV1 in the ICS mice model. EA alleviated FM-pain-like behaviors, possibly by abolishing the TRPV1- and IL-17A-related pathways. It suggests that EA is an effective and potential therapeutic strategy in FM.

neurosciences
Electroacupuncture at Fengchi(GB20) and Yanglingquan(GB34) Ameliorates Paralgesia through Microglia-Mediated Neuroinflammation in a Rat Model of Migraine

Min Zhou,Fang Pang,Dongmei Liao,Xinlu He,Yunhao Yang,Chenglin Tang

DOI: https://doi.org/10.3390/brainsci13040541

IF: 3.333

2023-03-25

Brain Sciences

Abstract:Background: Multiple studies have suggested that paralgesia (hyperalgesia and cutaneous allodynia) in migraine reflects the activation and sensitisation of the trigeminovascular system (TGVS). In particular, it reflects the second-order and higher nerve centre sensitisation, which is caused and maintained by neuroinflammation. Microglia activation leads to the release of proinflammatory cytokines involved in inflammatory responses. Accumulating evidence indicates that electroacupuncture (EA) is effective in ameliorating paralgesia, but the underlying mechanisms of EA in migraine attacks caused by microglia and microglia-mediated inflammatory responses are still unclear. The purpose of this study was to explore whether EA could ameliorate the dysregulation of pain sensation by suppressing microglial activation and the resulting neuroinflammatory response, and to evaluate whether this response was regulated by Toll-like receptor 4 (TLR4)/nuclear factor-kappa B(NF-κB) in the trigeminal nucleus caudalis (TNC) in a rat model of migraine. Methods: Repeated Inflammatory Soup (IS) was infused into the dura for seven sessions to establish a recurrent migraine-like rat model, and EA treatment was administered at Fengchi (GB20) and Yanglingquan (GB34) after daily IS infusion. Facial mechanical withdrawal thresholds were measured to evaluate the change in pain perception, and plasma samples and the TNC tissues of rats were collected to examine the changes in calcitonin gene-related peptide (CGRP), the Ibal-1-labelled microglial activation, and the resulting inflammatory response, including interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and their regulatory molecules TLR4/NF-κB, via enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC) and Western blot analysis. Results: Repeated IS injections into the dura induced facial mechanical paralgesia, which is the manifestation of migraine attacks, and increased the expression of CGRP, Ibal-1, microglial mediated inflammatory cytokines (IL-1β, TNF-α, IL-6), and regulatory molecules TLR4/NF-κB. EA at GB20/34 significantly attenuated repetitive IS-induced pain hypersensitivity. This effect was consistent with decreased levels of CGRP and inflammatory cytokines in the plasma and the TNC via the inhibition of microglia activation, and this response may be regulated by TLR4/NF-κB. Conclusions: EA ameliorated paralgesia in repetitive IS-induced migraine-like rats, which was mainly mediated by a reduction in microglial activation and microglial-mediated inflammatory responses that could be regulated by TLR4/NF-κB.

neurosciences
Epigenetic regulation of CIITA expression in human T-cells.

M. van Eggermond,Daan Boom,P. Klous,E. Schooten,V. Marquez,R. J. Wierda,T. Holling,P. J. van den Elsen

DOI: https://doi.org/10.1016/j.bcp.2011.05.026

IF: 6.1

2011-11-15

Biochemical Pharmacology

Abstract:
Successful Administration of Kampo Medicine and Acupuncture Treatment to Improve Erythromelalgia: A Case Report

Keisuke Kumada,Jun Matsumoto-Miyazaki,Hideshi Okada,Hiroyuki Okura,Yasumasa Sato

DOI: https://doi.org/10.7759/cureus.65890

2024-07-31

Cureus

Abstract:Erythromelalgia is a rare disease characterized by a triad of recurrent burning pain, redness with pain, and hot flashes in the legs during attacks. We report the case of a 40-year-old woman who suffered from refractory erythromelalgia for 15 years and was successfully managed with Kampo medicine and acupuncture. Her pain was refractory to seven types of oral medications and intravenous lidocaine injections. Byakkokaninjinto was also administered for concomitant polydipsia in addition to acupuncture, unseiin, orengedokuto, and sokeikakketsuto. Because erythromelalgia has no established treatment, traditional Kampo medicine combined with acupuncture may help improve the quality of life of affected patients.
A refractory anti-NMDA receptor encephalitis successfully treated by bilateral ovariectomy and intrathecal injection of methotrexate and dexamethasone: A case report

Dongmei Wang,Yongming Wu,Zhong Ji,Shengnan Wang,Yunqi Xu,Kaibin Huang,Yu Peng,Hui Zheng,Honghao Wang,Xiaomei Zhang,Suyue Pan

DOI: https://doi.org/10.21203/rs.2.9549/v1

2019-05-13

Abstract:Abstract Background: Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is an autoimmune-mediated disease, which is predominant in young female patients with ovarian teratomas. With proper immunotherapy, most of the patients achieve good prognosis. Nevertheless, some patients may be refractory to first and second-line immunotherapy, thus new treatments are required to help these patients. Case presentation: We present a case of anti-NMDA receptor encephalitis with ovary teratoma. After the prompt removal of the teratoma and strong immunotherapy including intravenous methylprednisolone pulse (IVMP), intravenous immunoglobin (IVIG), plasmapheresis, immunoadsorption, intravenous cyclophosphamide, and rituximab, the patient’s neurologic status did not improve. Bilateral ovariectomy was then conducted and intrathecal injection of methotrexate (MTX) and dexamethasone (DXM) was given. The patient’s neurological symptoms improved dramatically, and she achieved a good prognosis after 23 months. Conclusions: For refractory cases of anti-NMDA receptor encephalitis, intrathecal injection of MTX and DXM may be beneficial. More research is required to elucidate the mechanisms of intrathecal treatment.
Case report: successful epiradicular peripheral nerve stimulation of the C2 dorsal root ganglion for postherpetic neuralgia

Paul J Lynch,Tory McJunkin,Eric Eross,Stacie Gooch,Jillian Maloney

DOI: https://doi.org/10.1111/j.1525-1403.2010.00307.x

Neuromodulation

Abstract:Background: Postherpetic neuralgia (PHN) is the most common complication following an acute varicella zoster virus infection. PHN often results in a chronic severe pain condition refractory to conservative pain management treatments. Peripheral nerve stimulation over the affected spinal nerve root may be an effective treatment option for patients with intractable PHN. Objective: To describe a successful case of peripheral nerve stimulation of the second cervical dorsal root ganglion for the treatment of intractable PHN. Case report: An 80-year-old man with a 15-month history of severe PHN was referred to our clinic for pain management. His pain was localized to the left side in the distribution of the C2 dermatome. The patient's pain was unresponsive to comprehensive conventional treatments for PHN including physical therapy, membrane stabilizing medications, opioids, anti-inflammatories, cervical epidural steroid injections, cervical facet joint injections, and dorsal root ganglion blockade with pulsed radiofrequency. After failing to respond to conservative and interventional therapies, a peripheral nerve stimulator trial was conducted for a period of seven days. The lead was placed within the epidural space over the atlanto-axial joint under fluoroscopy to stimulate the left C2 nerve root. This trial resulted in a significant decrease of the patient's pain, and discontinuation of all pain medications. Conclusion: We describe a case of successful electrode placement at the C2 spinal level for the treatment of refractory PHN.
[Clofibrate: revocation of the revocation].

H. Holzgreve

1979-08-10

Abstract:
The effect of testosterone propionate on the connective tissue of the head appendices and the skin of the capon

J. Szirmai

DOI: https://doi.org/10.1002/ar.1091050209

1949-10-01

The Anatomical Record

Abstract:It is a well known fact that the connective tissue of certain skin formations of the liead and neck regions of birds are under the direct control of androgens. Vircliow (1851) mentioned the mucoid character of the connective tissue of the cock's comb. Histological investigations of more recent date, especially those of Champy and his collaborators ( '25, '26, '29)' Hardesty ( '31)' and Garrault ( '34) have proved that in the normal cock's comb there is an intermediate layer of characteristic mucoid connective tissue which depends on the presence of the male hormone. Heringa aiid TT'eidinger ( '40) have shown that the mucoid substance of this tissue is responsible for its typically high water-binding capacity. Herings ('48) has pointed out that the presence of the mucoid ground substance is also related to structural changes in the connective tissue fibrils, the connective tissue of the capon's comb containing predominantly dense collagenous fibers while that of the normal cock consists mainly of reticular fibrils. It is probable, however, that the sex hormones also influence the remaining skin and connective tissue. Some obser-
Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons

Yuanyuan Li,Chengyu Yin,Xiaojie Li,Boyu Liu,Jie Wang,Xiaoli Zheng,Xiaomei Shao,Yi Liang,Junying Du,Jianqiao Fang,Boyi Liu

DOI: https://doi.org/10.3390/ijms20235917

IF: 5.6

2019-11-25

International Journal of Molecular Sciences

Abstract:Paclitaxel-induced peripheral neuropathy is a common adverse effect during paclitaxel treatment resulting in sensory abnormalities and neuropathic pain during chemotherapy and in cancer survivors. Conventional therapies are usually ineffective and possess adverse effects. Here, we examined the effects of electroacupuncture (EA) on a rat model of paclitaxel-induced neuropathic pain and related mechanisms. EA robustly and persistently alleviated paclitaxel-induced pain hypersensitivities. Mechanistically, TLR4 (Toll-Like Receptor 4) and downstream signaling MyD88 (Myeloid Differentiation Primary Response 88) and TRPV1 (Transient Receptor Potential Vallinoid 1) were upregulated in dorsal root ganglion (DRGs) of paclitaxel-treated rats, whereas EA reduced their overexpression. Ca2+ imaging further indicated that TRPV1 channel activity was enhanced in DRG neurons of paclitaxel-treated rats whereas EA suppressed the enhanced TRPV1 channel activity. Pharmacological blocking of TRPV1 mimics the analgesic effects of EA on the pain hypersensitivities, whereas capsaicin reversed EA’s effect. Spinal astrocytes and microglia were activated in paclitaxel-treated rats, whereas EA reduced the activation. These results demonstrated that EA alleviates paclitaxel-induced peripheral neuropathic pain via mechanisms possibly involving suppressing TLR4 signaling and TRPV1 upregulation in DRG neurons, which further result in reduced spinal glia activation. Our work supports EA as a potential alternative therapy for paclitaxel-induced neuropathic pain.

biochemistry & molecular biology,chemistry, multidisciplinary
The efficacy and safety of epidural morphine/hydromorphone in the treatment of intractable postherpetic neuralgia: A single-center, double-blinded, randomized controlled, prospective, and non-inferiority study

Sun Yiping,Shen Jiayi,Hei Guang,Ji Yun,Ma Bingjie,Huang Xuehua,Yu Zhiyuan,Ma Pingchuan,Ma Ke

DOI: https://doi.org/10.3389/fphar.2022.1051357

IF: 5.6

2022-12-07

Frontiers in Pharmacology

Abstract:Objective: Postherpetic neuralgia (PHN) is a clinical puzzle, especially in patients who still suffered from moderate and severe pain after standard treatment. This single-center, double-blinded, randomized controlled, prospective, and non-inferiority study observed the safety and effectiveness of the epidural application of morphine or hydromorphone, trying to provide an alternative method for those patients with refractory PHN. Methods: Eighty PHN patients with a visual analogue scale (VAS) still greater than 50 mm after routine management were randomly divided into two groups according to 1:1, respectively. One group received epidural morphine (EMO group), and the other group received epidural hydromorphone (EHM group). VAS, the number of breakthrough pain, quality of life (QOL), and anxiety/depression assessment (GAD-7 and PHQ-9 scores) were also observed before treatment, at 1, 3, 7, 14, 21, 28, 60, and 90 days after treatment, as well as side effects. Opioid withdrawal symptoms (OWSs) were also measured from 3 to 28 days after treatment. Results: The EHM group was non-inferior to the EMO group in terms of the VAS decrease relative to baseline (VDRB) after 1-week treatment. The VAS of the two groups on all days after treatment was significantly lower than the corresponding baseline findings ( p 0.05). In terms of the QOL, GAD-7, and PHQ-9 outcomes, those were significantly improved after treatment ( p 0.05). No significant AE difference across the two groups was observed in this study. Few reports of OWS were found in this trial, and there were no significant differences between the two groups ( p > 0.05). Conclusion: EHM was non-inferior to EMO in terms of the VDRB after 1-week treatment. For patients with VAS still greater than 50 mm after standard treatment, short-term application of EMO or EHM can ameliorate intractable pain, improve the quality of life, and have no obvious side effects. Short-term epidural opioid application will not lead to the appearance of OWS.

pharmacology & pharmacy
Electroacupuncture improves allodynia and central sensitization via modulation of microglial activation associated P2X4R and inflammation in a rat model of migraine

Min Zhou,Fang Pang,Dongmei Liao,Yunhao Yang,Ying Wang,Zhuxin Yang,Xinlu He,Chenglin Tang

DOI: https://doi.org/10.1177/17448069241258113

IF: 3.37

2024-05-30

Molecular Pain

Abstract:Molecular Pain, Volume 20, Issue , January-December 2024. Background: Recent studies have demonstrated that activated microglia were involved in the pathogenesis of central sensitization characterized by cutaneous allodynia in migraine. Activation of microglia is accompanied by increased expression of its receptors and release of inflammatory mediators. Acupuncture and its developed electroacupuncture (EA) have been recommended as an alternative therapy for migraine and are widely used for relieving migraine-associated pain. However, it remains rare studies that show whether EA exerts anti-migraine effects via inhibiting microglial activation related to a release of microglial receptors and the inflammatory pathway. Therefore, this study aimed to investigate EA' ability to ameliorate central sensitization via modulation of microglial activation, microglial receptor, and inflammatory response using a rat model of migraine induced by repeated epidural chemical stimulation. Methods: In the present study, a rat model of migraine was established by epidural repeated inflammatory soup (IS) stimulation and treated with EA at Fengchi (GB20) and Yanglingquan (GB34) and acupuncture at sham-acupoints. Pain hypersensitivity was further determined by measuring the mechanical withdrawal threshold using the von-Frey filament. The changes in c-Fos and ionized calcium binding adaptor molecule 1 (Ibal-1) labeled microglia in the trigeminal nucleus caudalis (TNC) were examined by immunflurescence to assess the central sensitization and whether accompanied with microglia activation. In addition, the expression of Ibal-1, microglial purinoceptor P2X4, and its associated inflammatory signaling pathway mediators, including interleukin (IL)-1β, NOD-like receptor protein 3 (NLRP3), and Caspase-1 in the TNC were investigated by western blot and real-time polymerase chain reaction analysis. Results: Allodynia increased of c-Fos, and activated microglia were observed after repeated IS stimulation. EA alleviated the decrease in mechanical withdrawal thresholds, reduced the activation of c-Fos and microglia labeled with Ibal-1, downregulated the level of microglial purinoceptor P2X4, and limited the inflammatory response (NLRP3/Caspase-1/IL-1β signaling pathway) in the TNC of migraine rat model. Conclusions: Our results indicate that the anti-hyperalgesia effects of EA ameliorate central sensitization in IS-induced migraine by regulating microglial activation related to P2X4R and NLRP3/IL-1β inflammatory pathway.

neurosciences
P2Y12 receptor as a new target for electroacupuncture relieving comorbidity of visceral pain and depression of inflammatory bowel disease

Yanzhen Li,Hong Zhang,Jingwen Yang,Muouyang Zhan,Xuefei Hu,Yongmin Liu,Lingling Yu,Xiaochen Yan,Shangdong Liang,Ruyue Zhang,Ying Lu,Beining Li,Cunzhi Liu,Man Li

DOI: https://doi.org/10.1186/s13020-021-00553-9

IF: 4.546

2021-12-01

Chinese Medicine

Abstract:Abstract Background The P2Y12 receptor is a kind of purinoceptor that is engaged in platelet aggregation, and P2Y12 inhibitors have been used in clinical antithrombotic therapy. The P2Y12 receptor in microglia induces interleukin-1β (IL-1β) expression, which is a key mediator of depression in the brain. Although peripheral P2Y12 is involved in neuropathic pain, whether P2Y12 expression in the medial prefrontal cortex (mPFC) is associated with comorbidities of visceral pain and depression remains unclear. Accumulating evidence suggests that electroacupuncture (EA) is effective in treating inflammatory bowel disease (IBD), but its mechanism is unknown. This study aimed to determine whether P2Y12 expression in the mPFC is associated with comorbidities of visceral pain and depression in IBD and whether EA treats IBD by targeting the P2Y12 receptor. Methods We used 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced IBD mice. P2Y12 short hairpin RNA (shRNA) was stereotaxically injected into the bilateral mPFC. EA was performed on bilateral “Dachangshu” (BL25) acupoints once a day for 7 days. Von Frey filaments and colorectal distension were used to detect the mechanical pain threshold and visceral pain sensitivity. The sucrose preference test, tail suspension test and forced swimming test were used to evaluate depression in mice. Western blotting was used to test the expression of P2Y12 and IL-1β. Immunofluorescence staining was used to assess microglial activity. Results We found that IBD mice presented visceral pain and depression associated with increased P2Y12 expression in the mPFC. P2Y12 shRNA significantly attenuated visceral pain and depression in IBD mice. P2Y12 shRNA significantly downregulated IL-1β expression and inhibited the activation of microglia in the mPFC of IBD mice. Meanwhile, EA played a similar role of P2Y12 shRNA. EA significantly downregulated P2Y12 expression, weakened the activation of microglia, and then inhibited IL-1β expression in the mPFC, thus relieving visceral pain and depression in IBD mice. Conclusion The present study provided new ideas that the P2Y12 receptor in the mPFC could be a new target for the treatment of comorbid visceral pain and depression by EA. This may not only deepen our understanding of the analgesic and antidepressant mechanisms of EA but also promote the application of EA to treat IBD.

pharmacology & pharmacy,integrative & complementary medicine
Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: A systematic review and meta-analysis

Jianping Zhang,Aifang Fan,Lili Wei,Shihui Wei,Lindan Xie,Meixuan Li,Wenfang Zhang,Qin Liu,Kehu Yang

DOI: https://doi.org/10.1177/11206721211065218

2021-12-17

European Journal of Ophthalmology

Abstract:Background There are no systematic reviews yet that evaluated the effects of PE/IA in patients with optic neuritis (ON) in demyelinating diseases. A meta-analysis of available study is needed to further explore the value of plasma exchange (PE) or immunoadsorption (IA) in treating ON in demyelinating diseases. Methods All relevant articles published on PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), VIP Database, Wanfang, Sinomed and ophthalmology professional websites were searched. Study characteristics, demographic characteristics, clinical features and outcome measures were extracted. Response rate, adverse events (AE) rate, serious adverse event (SAE) rate, the log of the minimum angle of resolution (logMAR), visual outcome scale (VOS) and expanded disability status scales (EDSS) were evaluated using a random-effects model. Results 35 studies were included between 1985 and 2020, containing 1191 patients. The response rates of PE and IA in acute attack of ON were 68% and 82% respectively. LogMAR (−0.60 to − 1.42) and VOS (−1.10 to −1.82) had been significantly improved from within 1 month to more than 1 month after PE treatment. Besides, we found that logMAR improved 1.78, 0.95 and 0.38, respectively ,when the time from symptom onset to the first PE/IA was less than 21 days, 21–28 days, and more than 28 days. The pooled mean difference of EDSS was −1.14.Adverse effects rate in patients with PE or IA were 0.20 and 0.06, respectively. Conclusion The meta-analysis provided evidence that PE/IA treatment was an effective and safe intervention, and it is recommended that early initiation of PE/IA treatment is critical.

ophthalmology

P53immunostained cell nuclei segmentation in tissue images of oral squamous cell carcinoma

Effect of Ixekizumab on Enthesitis-related arthritis non-responsive to anti-TNF treatment, a case report

Efficacy of Paravertebral Injection of Interferon-α2b combined with High-Voltage Long-Term Pulsed Radiofrequency in DRG in mitigation of Postherpetic Neuralgia: A Retrospective Study

Electroacupuncture on Hemifacial Spasm and Temporomandibular Joint Pain Co-Morbidity: A Case Report

Primary erythromelalgia mainly manifested by hypertensive crisis: A case report and literature review

Procedural interventions for erythromelalgia: A narrative review

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World

A New Dosing Regimen of Ropeginterferon Alfa-2B is Highly Effective and Tolerable: Findings from a Phase 2 Study in Chinese Patients with Polycythemia Vera

Electroacupuncture Reduced Fibromyalgia-Pain-like Behavior through Inactivating Transient Receptor Potential V1 and Interleukin-17 in Intermittent Cold Stress Mice Model

Electroacupuncture at Fengchi(GB20) and Yanglingquan(GB34) Ameliorates Paralgesia through Microglia-Mediated Neuroinflammation in a Rat Model of Migraine

Epigenetic regulation of CIITA expression in human T-cells.

Successful Administration of Kampo Medicine and Acupuncture Treatment to Improve Erythromelalgia: A Case Report

A refractory anti-NMDA receptor encephalitis successfully treated by bilateral ovariectomy and intrathecal injection of methotrexate and dexamethasone: A case report

Case report: successful epiradicular peripheral nerve stimulation of the C2 dorsal root ganglion for postherpetic neuralgia

[Clofibrate: revocation of the revocation].

The effect of testosterone propionate on the connective tissue of the head appendices and the skin of the capon

Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons

The efficacy and safety of epidural morphine/hydromorphone in the treatment of intractable postherpetic neuralgia: A single-center, double-blinded, randomized controlled, prospective, and non-inferiority study

Electroacupuncture improves allodynia and central sensitization via modulation of microglial activation associated P2X4R and inflammation in a rat model of migraine

P2Y12 receptor as a new target for electroacupuncture relieving comorbidity of visceral pain and depression of inflammatory bowel disease

Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: A systematic review and meta-analysis